Long noncoding RNA LINC00518 induces radioresistance by regulating glycolysis through an miR-33a-3p/HIF-1α negative feedback loop in melanoma.
Animals
Cell Line, Tumor
Cell Movement
Cell Proliferation
Databases, Genetic
Feedback, Physiological
Gene Expression Regulation, Neoplastic
Glycolysis
Humans
Hypoxia-Inducible Factor 1, alpha Subunit
/ genetics
Male
Melanoma
/ genetics
Mice, Inbred BALB C
Mice, Nude
MicroRNAs
/ genetics
Neoplasm Invasiveness
RNA, Long Noncoding
/ genetics
Radiation Tolerance
Signal Transduction
Skin Neoplasms
/ genetics
Tumor Hypoxia
Tumor Microenvironment
Xenograft Model Antitumor Assays
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
04 03 2021
04 03 2021
Historique:
received:
16
08
2020
accepted:
09
02
2021
revised:
07
02
2021
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
14
9
2021
Statut:
epublish
Résumé
The long noncoding RNA, LINC00518, is highly expressed in various types of cancers and is involved in cancer progression. Although LINC00518 promotes the metastasis of cutaneous malignant melanoma (CMM), the mechanism underlaying its effects on CMM radiosensitivity remains unclear. In this study, LINC00518 expression was significantly upregulated in CMM samples, and LINC00518 levels were associated with poor prognosis of patients with CMM. Knockdown of LINC00518 in CMM cells significantly inhibited cell invasion, migration, proliferation, and clonogenicity. LINC00518-mediated invasion, migration, proliferation, and clonogenicity were negatively regulated by the microRNA, miR-33a-3p, in vitro, which increased sensitivity to radiotherapy via inhibition of the hypoxia-inducible factor 1α (HIF-1α)/lactate dehydrogenase A glycolysis axis. Additionally, HIF-1α recognized the miR-33a-3p promoter region and recruited histone deacetylase 2, which decreased the expression of miR-33a-3p and formed an LINC00518/miR-33a-3p/HIF-1α negative feedback loop. Furthermore, signaling with initially activated glycolysis and radioresistance in CMM cells was impaired by Santacruzamate A, a histone deacetylase inhibitor, and 2-deoxy-D-glucose, a glycolytic inhibitor. Lastly, knockdown of LINC00518 expression sensitized CMM cancer cells to radiotherapy in an in vivo subcutaneously implanted tumor model. In conclusion, LINC00518 was confirmed to be an oncogene in CMM, which induces radioresistance by regulating glycolysis through an miR-33a-3p/HIF-1α negative feedback loop. Our study, may provide a potential strategy to improve the treatment outcome of radiotherapy in CMM.
Identifiants
pubmed: 33664256
doi: 10.1038/s41419-021-03523-z
pii: 10.1038/s41419-021-03523-z
pmc: PMC7933330
doi:
Substances chimiques
HIF1A protein, human
0
Hypoxia-Inducible Factor 1, alpha Subunit
0
MIRN33a microRNA, human
0
MicroRNAs
0
RNA, Long Noncoding
0
long non-coding RNA LINC00518, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
245Références
Schadendorf, D. et al. Melanoma. Nat. Rev. Dis. 1, 1–20 (2015).
Rastrelli, M., Tropea, S., Rossi, C. & Alaibac, M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo 28, 1005–1011 (2014).
pubmed: 25398793
Lee, C., Thoma, C. & Ng, K. An overview of the changing landscape of treatment for advanced melanoma. Pharmacotherapy 37, 319–333 (2017).
pubmed: 28052356
doi: 10.1002/phar.1895
Eggermont, A., Spatz, A. & Robert, C. Cutaneous melanoma. Lancet 383, 816–827 (2014).
pubmed: 24054424
doi: 10.1016/S0140-6736(13)60802-8
Balch, C., Gershenwald, J., Soong, S., Thompson, J. & Atkins, M. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 199–6206 (2009).
doi: 10.1200/JCO.2009.23.4799
Mendenhall, W. et al. Adjuvant postoperative radiotherapy for cutaneous melanoma. Acta Oncol. 56, 495–496 (2017).
pubmed: 28256960
doi: 10.1080/0284186X.2017.1295168
Beadle, B. et al. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int. J. Radiat. Oncol. Biol. Phys. 73, 1376–1382 (2009).
pubmed: 18774657
doi: 10.1016/j.ijrobp.2008.06.1910
Mahadevan, A., Patel, V. & Dagoglu, N. Radiation therapy in the management of malignant melanoma. Oncology 29, 743–751 (2015).
pubmed: 26470898
Maverakis, E., Cornelius, L., Bowen, G., Phan, T. & Patel, F. B. Metastatic melanoma—a review of current and future treatment options. Acta Derm. Venereol. 95, 516–524 (2015).
pubmed: 25520039
doi: 10.2340/00015555-2035
Gilkes, D., Semenza, G. & Wirtz, D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat. Rev. Cancer 14, 430–439 (2014).
pubmed: 24827502
pmcid: 4283800
doi: 10.1038/nrc3726
Barker, H., Paget, J., Khan, A. & Harrington, K. The tumour microenvironmentafter radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15, 409–425 (2015).
pubmed: 26105538
pmcid: 4896389
doi: 10.1038/nrc3958
Macklin, P., McAuliffe, J., Pugh, C. & Yamamoto, A. Hypoxia and HIF pathway in cancer and the placenta. Placenta 56, 8–13 (2017).
pubmed: 28330647
doi: 10.1016/j.placenta.2017.03.010
Parks, S., Cormerais, Y. & Pouysségur, J. Hypoxia and cellular metabolism in tumour pathophysiology. J. Physiol. 595, 2439–2450 (2017).
pubmed: 28074546
pmcid: 5390873
doi: 10.1113/JP273309
Hanahan, D. & Weinberg, R. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
Nys, K., Maes, H., Dudek, A. & Agostinis, P. Uncovering the role of hypoxia inducible factor-1alpha in skin carcinogenesis. Biochim. Piophys. Acta 1816, 1–12 (2011).
Kuphal, S., Winklmeier, A., Warnecke, C. & Bosserhoff, A. Constitutive HIF-1 activity in malignant melanoma. Eur. J. Cancer 46, 1159–1169 (2010).
pubmed: 20185296
doi: 10.1016/j.ejca.2010.01.031
Fan, J. et al. Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Mol. Cell Biol. 31, 4938–4950 (2011).
pubmed: 21969607
pmcid: 3233034
doi: 10.1128/MCB.06120-11
Ke, Q. & Costa, M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 70, 1469–1480 (2006).
pubmed: 16887934
doi: 10.1124/mol.106.027029
Meijer, T., Kaanders, J., Span, P. & Bussink, J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin. Cancer Res. 18, 5585–5594 (2012).
pubmed: 23071360
doi: 10.1158/1078-0432.CCR-12-0858
Zhao, F., Ming, J., Zhou, Y. & Fan, L. Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation. Cancer Chemother. Pharmacol. 77, 963–972 (2016).
pubmed: 27011212
doi: 10.1007/s00280-016-3007-9
Shimura, T. et al. AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells. Radiother. Oncol. 112, 302–307 (2014).
pubmed: 25150637
doi: 10.1016/j.radonc.2014.07.015
Huang, X. et al. HK2 is a radiation resistant and independent negative prognostic factor for patients with locally advanced cervical squamous cell carcinoma. Int. J. Clin. Exp. Pathol. 8, 4054–4063 (2015).
pubmed: 26097593
pmcid: 4466980
Quinn, J. & Chang, H. Unique features of long non-coding RNA biogenesis and function. Nat. Rev. Genet. 17, 47–62 (2016).
pubmed: 26666209
doi: 10.1038/nrg.2015.10
Jarroux, J., Morillon, A. & Pinskaya, M. History, discovery, and classification of lncRNAs. Adv. Exp. Med. Biol. 1008, 1–46 (2017).
pubmed: 28815535
doi: 10.1007/978-981-10-5203-3_1
Xiang, S. et al. LncRNA IDH1-AS1 links the functions of c-Myc and HIF-1α via IDH1 to regulate the Warburg effect. Proc. Natl Acad. Sci. USA 115, 1465–1474 (2018).
doi: 10.1073/pnas.1711257115
Yang, F., Zhang, H., Mei, Y. & Wu, M. Reciprocal regulation of HIF-1α and LINCRNA-p21 modulates the Warburg effect. Mol. Cell. 53, 88–100 (2014).
pubmed: 24316222
doi: 10.1016/j.molcel.2013.11.004
Leonardo, S., Laura, P., Yvonne, T., Lev, K. & Pier, P. A ceRNA hypothesis: the Rosetta stone of a hidden RNA language? Cell 146, 353–358 (2011).
doi: 10.1016/j.cell.2011.07.014
Zhang, P., Cao, L., Fan, P., Mei, Y. & Wu, M. LncRNA-MIF, a c-Myc-activated long non-coding RNA, suppresses glycolysis by promoting Fbxw7-mediated c-Myc degradation. EMBO Rep. 17, 1204–1220 (2016).
pubmed: 27317567
pmcid: 4967955
doi: 10.15252/embr.201642067
Lin, Y. et al. Taurine up-regulated gene 1 functions as a master regulator to coordinate glycolysis and metastasis in hepatocellular carcinoma. Hepatology 67, 188–203 (2018).
pubmed: 28802060
doi: 10.1002/hep.29462
Leucci, E., Coe, E., Marine, J. & Vance, K. The emerging role of long non-coding RNAs in cutaneous melanoma. Pigment Cell Melanoma Res. 29, 619–626 (2016).
pubmed: 27606977
doi: 10.1111/pcmr.12537
Kabbarah, O. et al. Integrative genome comparison of primary and metastatic melanomas. PLoS ONE 5, 5–2 (2010).
doi: 10.1371/journal.pone.0010770
Smith, A., Hoek, K. & Becker, D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol. Ther. 4, 1018–1029 (2005).
pubmed: 16251803
doi: 10.4161/cbt.4.9.2165
Luan, W. et al. Long noncoding RNA LINC00518 acts as a competing endogenous RNA to promote the metastasis of malignant melanoma via miR-204-5p/AP1S2 axis. Cell Death Dis. 10, 855–867 (2019).
pubmed: 31712557
pmcid: 6848151
doi: 10.1038/s41419-019-2090-3
Oliveira, S., Yang, L., Echevarria-Lima, J., Monteiro, R. Q. & Rezaie, A. R. Thrombomodulin modulates cell migration in human melanoma cell lines. Melanoma Res. 24, 11–19 (2014).
doi: 10.1097/CMR.0000000000000035
Wang, Z. et al. Association of EGFR gene fragments with nuclear matrix proteins in high and low metastatic melanoma cell lines. Anticancer Res. 19, 4349–4352 (1999).
pubmed: 10628399
Chang, L., Hu, Z., Zhou, Z. & Zhang, H. Linc00518 contributes to multidrug resistance through regulating the MiR-199a/MRP1 axis in breast cancer. Cell Physiol. Biochem. 48, 16–28 (2018).
pubmed: 30001527
doi: 10.1159/000491659
Wang, D., You, D., Dong, J. & Liu, F. Knockdown of long non-coding RNA LINC00518 inhibits cervical cancer proliferation and metastasis by modulating JAK/STAT3 signaling. Eur. Rev. Med. Pharm. Sci. 23, 496–506 (2019).
Zhou, J. et al. MiR-33a functions as a tumor suppressor in melanoma by targeting HIF-1α. Cancer Biol. Ther. 16, 846–855 (2015).
pubmed: 25891797
pmcid: 4622471
doi: 10.1080/15384047.2015.1030545
Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834–840 (2009).
pubmed: 19608861
doi: 10.1126/science.1175371
Magnon, C., Opolon, P. & Schlumberger, M. Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1alpha-mediated tumor apoptotic switch. J. Clin. Invest. 117, 1844–1855 (2007).
pubmed: 17557121
pmcid: 1884687
doi: 10.1172/JCI30269
Gerami, P. et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J. Am. Acad. Dermatol. 76, 114–120 (2017).
pubmed: 27707590
doi: 10.1016/j.jaad.2016.07.038
Ferris, L. et al. Utility of a noninvasive 2-gene molecular assay for cutaneous melanoma and effect on the decision to biopsy. JAMA Dermatol. 153, 675–680 (2017).
pubmed: 28445578
pmcid: 5543318
doi: 10.1001/jamadermatol.2017.0473
Yu, J. et al. Upregulated long non-coding RNA LINC00152 expression is associated with progression and poor prognosis of tongue squamous cell carcinoma. J. Cancer 8, 523–530 (2017).
pubmed: 28367232
pmcid: 5370496
doi: 10.7150/jca.17510
Zhu, Y. et al. The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway. Oncogene 38, 6065–6081 (2019).
pubmed: 31273338
doi: 10.1038/s41388-019-0858-7
Tay, Y., Rinn, J. & Pandolfi, P. P. The multilayered complexity of ceRNA crosstalk and competition. Nature 505, 344–352 (2014).
pubmed: 24429633
pmcid: 4113481
doi: 10.1038/nature12986
Qi, X. et al. CeRNA in cancer: possible functions and clinical implications. J. Med. Genet. 52, 710–718 (510).
Chen, H., Du, G., Song, X. & Li, L. Non-coding transcripts from enhancers: new insights into enhancer activity and gene expression regulation. Genom. Proteom. Bioinform. 15, 201–207 (2017).
doi: 10.1016/j.gpb.2017.02.003
Moussaieff, A., Rouleau, M., Aberdam, D. & Nahmias, Y. Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells. Cell Metab. 21, 392–402 (2015).
pubmed: 25738455
doi: 10.1016/j.cmet.2015.02.002
Zhang, E., Han, L., Yin, D., Shu, Y. & Chen, J. H3K27 acetylation activated-long non-coding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinoma. Nucleic Acids Res. 45, 3086–3101 (2017).
pubmed: 27956498
doi: 10.1093/nar/gkw1247
Schoepflin, Z., Shapiro, I. & Risbud, M. Class I. and IIa HDACs mediate HIF-1α stability through PHD2-dependent mechanism, while HDAC6, a class IIb member, promotes HIF-1α transcriptional activity in nucleus pulposus cells of the intervertebral disc. J. Bone Miner. Res. 31, 1287–1299 (2016).
pubmed: 26765925
doi: 10.1002/jbmr.2787
Krumm, A. et al. Enhanced histone deacetylase activity in malignant melanoma provokes RAD51 and FANCD2-triggered drug resistance. Cancer Res. 76, 3067–3077 (2016).
pubmed: 26980768
doi: 10.1158/0008-5472.CAN-15-2680
Han, S. et al. MicroRNA-33a-3p suppresses cell migration and invasion by directly targeting PBX3 in human hepatocellular carcinoma. Oncotarget 7, 42461–42473 (2016).
pubmed: 27285759
pmcid: 5173148
doi: 10.18632/oncotarget.9886
Liang, M., Liu, Z., Lin, H., Shi, B. & Li, M. Chen T. High-throughput sequencing reveals circular RNA hsa_circ_0000592 as a novel player in the carcinogenesis of gastric carcinoma. Biosci. Rep. 39, 623–641 (2019).
doi: 10.1042/BSR20181900
Akram, M. et al. Mini-review on glycolysis and cancer. J. Cancer Educ. 28, 454–457 (2013).
pubmed: 23728993
doi: 10.1007/s13187-013-0486-9
Ganapathy, S. & Geschwind, J. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol. Cancer 12, 52–159 (2013).
Görlach, A., Dimova, E., Petry, A. & Martínez-Ruiz, A. Reactive oxygen species, nutrition, hypoxia and diseases: problems solved? Redox Biol. 6, 372–385 (2015).
pubmed: 26339717
pmcid: 4565025
doi: 10.1016/j.redox.2015.08.016
Nosrati, N., Bakovic, M. & Paliyath, G. Molecular mechanisms and pathways as targets for cancer prevention and progression with dietary compounds. Int. J. Mol. Sci. 18, 57–63 (2017).
doi: 10.3390/ijms18102050
Valencak, J., Kittler, H. & Gonzalez-Inchaurraga, M. Prognostic relevance of hypoxia inducible factor-1alpha expression in patients with melanoma. Clin. Exp. Dermatol. 34, e962–e964 (2009).
pubmed: 20055873
doi: 10.1111/j.1365-2230.2009.03706.x
Zeng, Q. et al. Inhibition of REDD1 sensitizes bladder urothelial carcinoma to paclitaxel by inhibiting autophagy. Clin. Cancer Res. 24, 445–459 (2018).
pubmed: 29084921
doi: 10.1158/1078-0432.CCR-17-0419
Li, W. et al. TRAF4 is a critical molecule for Akt activation in lung cancer. Cancer Res. 73, 6938–6950 (2013).
pubmed: 24154876
doi: 10.1158/0008-5472.CAN-13-0913
Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J. & van Bree, C. Clonogenic assay of cells in vitro. Nat. Protoc. 5, 2315–2319 (2006).
doi: 10.1038/nprot.2006.339